Stock Research for AZNCF

AZNCF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AZNCF Stock Chart & Research Data

The AZNCF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AZNCF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AZNCF Due diligence Resources & Stock Charts

The AZNCF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AZNCF Detailed Price Forecast - CNN Money CNN View AZNCF Detailed Summary - Google Finance
Yahoo View AZNCF Detailed Summary - Yahoo! Finance Zacks View AZNCF Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View AZNCF Trends & Analysis - Trade-Ideas Barrons View AZNCF Major Holders - Barrons
NASDAQ View AZNCF Call Transcripts - NASDAQ Seeking View AZNCF Breaking News & Analysis - Seeking Alpha
Spotlight View AZNCF Annual Report - CompanySpotlight.com OTC Report View AZNCF OTC Short Report - OTCShortReport.com
TradeKing View AZNCF Fundamentals - TradeKing Charts View AZNCF SEC Filings - Bar Chart
WSJ View Historical Prices for AZNCF - The WSJ Morningstar View Performance/Total Return for AZNCF - Morningstar
MarketWatch View the Analyst Estimates for AZNCF - MarketWatch CNBC View the Earnings History for AZNCF - CNBC
StockMarketWatch View the AZNCF Earnings - StockMarketWatch MacroAxis View AZNCF Buy or Sell Recommendations - MacroAxis
Bullish View the AZNCF Bullish Patterns - American Bulls Short Pains View AZNCF Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View AZNCF Stock Mentions - StockTwits PennyStocks View AZNCF Stock Mentions - PennyStockTweets
Twitter View AZNCF Stock Mentions - Twitter Invest Hub View AZNCF Investment Forum News - Investor Hub
Yahoo View AZNCF Stock Mentions - Yahoo! Message Board Seeking Alpha View AZNCF Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for AZNCF - SECform4.com Insider Cow View Insider Transactions for AZNCF - Insider Cow
CNBC View AZNCF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AZNCF - OTC Markets
Yahoo View Insider Transactions for AZNCF - Yahoo! Finance NASDAQ View Institutional Holdings for AZNCF - NASDAQ


Stock Charts

FinViz View AZNCF Stock Insight & Charts - FinViz.com StockCharts View AZNCF Investment Charts - StockCharts.com
BarChart View AZNCF Stock Overview & Charts - BarChart Trading View View AZNCF User Generated Charts - Trading View


Latest Financial News for AZNCF

Long-Term Investors Take Note -- These 5 Big Pharma Companies Have the Best Pipelines
Posted on Sunday June 24, 2018

These drugmakers arguably have the strongest pipelines. But are they all great stocks to buy?


Lynparza Could Be Merck’s Long-Term Growth Driver
Posted on Wednesday June 20, 2018

Merck & Company (MRK) and AstraZeneca (AZN) jointly develop and commercialize Lynparza. In June, Merck and AstraZeneca presented data from the Study 08 trial, in which a combination of Lynparza and abiraterone demonstrated an improvement in median radiologic progression-free survival (or rPFS) compared to abiraterone monotherapy.


Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
Posted on Friday June 15, 2018

Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.


[$$] Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer’s Drug Trials
Posted on Tuesday June 12, 2018

AstraZeneca PLC and Eli Lilly & Co. on Tuesday scrapped two late-stage trials of an experimental Alzheimer’s drug they were co-developing, the latest blow in the long quest to find a breakthrough for the memory-robbing disorder. The companies said the decision was taken after an independent data-monitoring committee concluded that trials associated with lanabecestat, the experimental drug, wouldn’t achieve their original goals. An AstraZeneca spokesman said the two will continue to jointly pursue an early-stage trial of another experimental Alzheimer’s drug.


Enter a stock symbol to view the stock details.